secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0000950170-24-027111
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports FY2023 net loss $78.6M; cash runway into 2026 after $80M offering
--------------------------------------------------------------------------------

- Enrollment complete for PGN-EDO51 5 mg/kg cohort; preliminary data expected mid-2024.
- CONNECT2-EDO51 Phase 2 trial for DMD initiated in UK; designed to support accelerated approval.
- FREEDOM-DM1 Phase 1 trial enrolling; preliminary data from 5 mg/kg cohort expected H2 2024.
- Cash $110.4M as of Dec 31, 2023; combined with $80M Feb 2024 offering extends runway into 2026.
- Net loss $78.6M for FY2023 vs $69.1M in FY2022; R&D expenses $68.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/0000950170-24-027111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/pepg-20240306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-027111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer